IMM.AX stock A$0.051, 57.80M shares on ASX: trial results and legal probes

IMM.AX stock closed at A$0.051 on the ASX on 20 Mar 2026 after 57,803,121 shares changed hands, making it one of the market’s most active small-caps today. Immutep Limited (IMM.AX) sits at a crossroads after a strong Phase I update for IMP761 and multiple investor lawsuits and investigations tied to the halted TACTI-004 trial. We summarise the trading action, clinical news, regulatory notices, and what this means for valuation and near-term catalysts using Meyka AI’s real-time market analysis platform.

IMM.AX stock trading and volume

Immutep Limited (IMM.AX) led ASX activity on 20 Mar 2026 with volume 57,803,121 versus an average daily volume of 17,460,252. The stock opened at A$0.051, hit a day low of A$0.049 and a high of A$0.056, and closed slightly down from yesterday’s A$0.052. High turnover reflects forced selling and headline-driven flows after the Phase III futility notice and subsequent legal alerts. Traders should note the relative volume, at roughly 3.31x the norm, signals elevated liquidity and volatility in the short term.

Clinical update: IMP761 Phase I progress and market impact

Immutep announced completion of the SAD portion of the IMP761 Phase I study and reported the drug was well tolerated up to 14 mg/kg. The company said durable T-cell inhibition was observed and that full Phase I results will be presented at EULAR on 4 June 2026. That positive autoimmune program update contrasts with the halted TACTI-004 oncology trial and has split investor reaction. The IMP761 news supports longer-term opportunity in autoimmune indications but has not offset near-term confidence lost after the Phase III stop. See the clinical release for details source.

Legal notices and investor investigations pressuring IMM.AX stock

Following the TACTI-004 futility announcement, several law firms have opened securities investigations into Immutep’s disclosures. Notices from Levi & Korsinsky and Rosen Law Firm highlight potential gaps between prior filings and the March interim IDMC decision. These legal developments have amplified selling pressure and contributed to the stock’s steep moves. Investors should monitor filings and potential litigation outcomes because legal actions can prolong volatility and affect capital structure and investor sentiment. The investigation notice is available source.

Financials, valuation and key ratios

At A$0.051, Immutep’s market cap is about A$75.07 million with 1,471,920,338 shares outstanding. Trailing EPS is -0.01 and the reported PE is -5.10. Balance-sheet metrics show a current ratio 2.97 and cash per share A$0.0674, which provides working capital runway but not earnings support. Price-to-book stands at 0.76, while price-to-sales is 12.56. Research and development intensity remains high at ~6.04x revenue, reflecting biotech-stage spending. These metrics explain why valuation is driven by binary clinical outcomes rather than steady revenue growth.

Technical picture and trading setup

The technicals show heavy downside momentum and oversold conditions. RSI is 14.65 (oversold) and MACD is negative with a histogram of -0.04. Bollinger Bands range is wide with middle band at A$0.30, but current price sits near the lower band A$0.01, underscoring deep discounting versus moving averages. Short-term traders see both risk and opportunity: tight risk management is essential given ATR A$0.03 and a fast-moving trend (ADX 32.02). A rebound trade would rely on stabilising news flow or clearer readouts on IMP761 and trial wind-downs.

Meyka AI grade, model forecasts and analyst context

Meyka AI rates IMM.AX with a score out of 100. Meyka AI rates IMM.AX with a score of 62.20 / 100, Grade B, Suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Note independent company ratings list a C- (Strong Sell) as of 19 Mar 2026, reflecting diverging views.

Meyka AI’s forecast model projects a yearly price of A$0.3532 and a monthly median of A$0.34, with a quarterly scenario at A$0.45. Compared to the current price A$0.051, the yearly projection implies an upside of ~592.95%. Forecasts are model-based projections and not guarantees. For an up-to-date company page, see Immutep on Meyka Internal link.

Final Thoughts

IMM.AX stock finished the session at A$0.051 on ASX with 57,803,121 shares traded, driven by a split between fresh clinical optimism for IMP761 and sharp investor reaction to the TACTI-004 futility decision and related legal notices. Financial metrics show limited near-term earnings and a small market cap (A$75.07 million), so price action will remain sensitive to binary news. Meyka AI’s forecast model projects a yearly price of A$0.3532, implying a modelled upside of ~592.95% versus today’s A$0.051; however, this outcome depends on successful clinical follow-ups, litigation outcomes, and funding. Risk-aware investors should weigh the high volatility, thin free-float dynamics, and mixed analyst signals — the Meyka grade (B, HOLD) highlights the stock’s speculative nature. Monitor announced data presentations, regulatory filings, and trial wind-down updates for clearer direction before increasing exposure.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.